Visa Launches Scam Disruption, Tap to Phone Surge and Pilot Stablecoin Payouts While Facing DOJ Lawsuit
Visa unveiled a scam disruption initiative and saw rapid adoption of its Tap to Phone technology, while also expanding its digital currency capabilities with a pilot program enabling payouts to stablecoin wallets. The payments processor now faces a Department of Justice antitrust lawsuit and bipartisan congressional support to challenge its merchant network duopoly.
1. Recent Market Underperformance
Visa’s shares declined by 1.33% in the latest trading session, underperforming broader market gains and signaling investor caution. Trading volume rose 12% above its 30-day average, suggesting profit-taking following a multi-month rally. Analysts attribute the pullback to concerns over near-term consumer spending trends and ongoing regulatory scrutiny, with the Justice Department’s antitrust lawsuit and Congressional proposals targeting credit-card fee structures weighing on sentiment.
2. Strategic Growth Initiatives
This year, Visa rolled out a global scam disruption platform that has already prevented over 2.5 million fraudulent transactions, reducing estimated annual losses by $150 million. Adoption of its Tap-to-Phone technology has surged 80% quarter-over-quarter, unlocking acceptance at 200,000 additional merchant locations. The company has also launched a pilot enabling direct payouts to stablecoin wallets and disclosed plans to integrate AI-driven transaction analytics across its network by mid-2026, reinforcing its leadership in digital payments.
3. Financial Trajectory and Analyst Outlook
Visa reported full-year revenue growth of 10.5%, with net income rising 14% to approximately $19.7 billion, driven by a 9% increase in processed transactions to 250 billion. It has sustained a dividend CAGR of 17.2% over the past decade, increasing per-share payouts from $0.13 in 2013 to $2.68 today. Consensus forecasts from 40 analysts project mid-single-digit revenue growth through 2026, with median EPS estimates climbing to $13.07 next year. The current consensus one-year price target implies roughly 12% upside potential for patient investors.